Short answer
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed an 8-K current report with the SEC on February 24, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events). Q1 2025 earnings results disclosed via press release in Exhibit 99.1.
IOVANCE BIOTHERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2025 earnings results disclosed via press release in Exhibit 99.1
- Exhibit filed under Reg FD safe harbor: not subject to Section 18 liability, limiting legal exposure for investors relying on it
- Full financial details (revenue, EPS, guidance) contained in Exhibit 99.1
Item 8.01 · Other Events
- Updated corporate presentation filed Feb 24, 2026: potential signal of new strategic messaging or data to analysts and investors
- Full substance in Exhibit 99.2; investors should review for pipeline updates, commercial metrics, or guidance changes
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other IOVANCE BIOTHERAPEUTICS, INC. 8-K filings
Get the next IOVA 8-K as it lands
Follow IOVA for push alerts, or ask the research agent what this filing means.